Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

168.92 +0.94 (+0.56%)
Streaming Delayed Price Updated: 3:43 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
News headline image
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday. 
Via Investor's Business Daily
News headline image
3 Small-Cap Stocks Skating on Thin Ice
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
CrowdStrike To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Earnings To Watch: Amphastar Pharmaceuticals (AMPH) Reports Q4 Results Tomorrow
Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) will be reporting earnings tomorrow after market hours. Here’s what to expect. 
Via StockStory
News headline image
Viatris Earnings: What To Look For From VTRS
Medication company Viatris (NASDAQ:VTRS) will be reporting results tomorrow before market open. Here’s what to expect. 
Via StockStory
News headline image
Earnings Scheduled For February 25, 2025 ↗
 
Via Benzinga
News headline image
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
NASDAQ:JAZZ, an undervalued stock with good fundamentals. ↗
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ): good value for what you're paying. 
Via Chartmill
News headline image
Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 Sales
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.5% year on year to $1.09 billion. On the other hand, the company’s full-year... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
News headline image
NASDAQ:JAZZ is probably undervalued for the fundamentals it is displaying. ↗
JAZZ PHARMACEUTICALS PLC may be an undervalued stock option. NASDAQ:JAZZ retains a strong financial foundation and an attractive price tag. 
Via Chartmill
News headline image
This AstraZeneca Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
 
Via Benzinga
News headline image
Investors should take notice of NASDAQ:JAZZ—it offers a great deal for the fundamentals it presents. ↗
When you look at JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ), it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. 
Via Chartmill
News headline image
In-Depth Examination Of 12 Analyst Recommendations For Jazz Pharmaceuticals ↗
 
Via Benzinga
News headline image
Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts ↗
 
Via Benzinga
News headline image
NASDAQ:JAZZ, an undervalued stock with good fundamentals. ↗
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
NASDAQ:JAZZ is an undervalued gem with solid fundamentals. ↗
Investors should take notice ofJAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ)—it offers a great deal for the fundamentals it presents. 
Via Chartmill
News headline image
CBD Drug For Tuberous Sclerosis: Caregivers Continue Epidiolex Treatment Citing Seizure Reduction And Cognitive Improvements ↗
The majority of caregivers of patients with tuberous sclerosis complex (TSC) planned to continue Epidiolex treatment, citing benefits like reduced seizure frequency and improvements in cognition and... 
Via Benzinga
News headline image
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says ↗
Axsome's AXS-12 met Phase 3 trial goals, cutting cataplexy attacks by 77% over six months and improving cognition with a favorable safety profile. 
Via Benzinga
News headline image
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
For those who appreciate value investing, JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is a compelling option with its solid fundamentals. 
Via Chartmill
News headline image
Despite its impressive fundamentals, NASDAQ:JAZZ remains undervalued. ↗
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
A Closer Look at 12 Analyst Recommendations For Jazz Pharmaceuticals ↗
 
Via Benzinga
News headline image
FDA Greenlights Jazz Pharma's Cancer Drug, A Milestone For Zymework ↗
Jazz Pharmaceuticals' Ziihera receives FDA accelerated approval for HER2-positive BTC. Phase 3 trial ongoing; Zymeworks secures $25 million milestone. 
Via Benzinga
News headline image
UK Parents Want National Health Service To Allow Cannabis For Children With Epilepsy ↗
 
Via Benzinga
Topics Cannabis
News headline image
Jazz Pharmaceuticals Reports Strong Q3: Will Debt Weigh On Its Future Growth? ↗
CEO Bruce Cozadd emphasized that Jazz remains "confident in its revenue guidance of $4.0 to $4.1 billion" for the full year. 
Via Benzinga
News headline image
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker ↗
Ardent value investor Seth Klarman is swapping out shares of search engine juggernaut Alphabet for a relatively unknown pharmaceutical stock that has a forward price-to-earnings ratio of 5! 
Via The Motley Fool
News headline image
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung Cancer ↗
Jazz Pharmaceuticals released Phase 3 trial results for Zepzelca in combination with Roche's atezolizumab as a maintenance treatment for extensive-stage small-cell lung cancer. Jazz plans to submit a... 
Via Benzinga
News headline image
NASDAQ:JAZZ is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
News headline image
FDA-Approved Cannabis-Based Drug Shows Promising Results As A Treatment For War Veterans: Study Finds Improvement In Cognitive, Mood, Pain-Related Symptoms ↗
Veterans: Epidiolex shows promise in treating Gulf War Illness, offering hope for those affected. Learn how it might benefit them. 
Via Benzinga
News headline image
When you look at NASDAQ:JAZZ, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) is an undervalued gem with solid fundamentals. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.